Cancers, Vol. 13, Pages 2529: Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

The objective response rates (ORRs) to combined BRAFi plus MEKi and to BRAFi mono-therapy were 57.4% and 39.8%, respectively. The median progression-free survival (PFS) and median overall survival (OS) were 9.2 months and 22.6 months, respectively, for the combined first-line therapy; 9.4 months and 16.1 months, respectively, for the combined second-line therapy; and 7.4 months and 17.1 months, respectively, for the combined third- or higher-line therapy. Analysis of treatment patterns demonstrated the effectiveness of the combined TT with BRAF plus MEK inhibitors in patients with brain metastases, rare types of BRAF mutations, and across lines of therapy, as well as a well-tolerated and manageable safety profile.

Source: Cancers - May 21, 2021 Category: Cancer & Oncology Authors: Kristina V. Orlova Evgeniy V. Ledin Natalia V. Zhukova Rashida V. Orlova Elena V. Karabina Mikhail V. Volkonskiy Daniil L. Stroyakovskiy Aleksandr N. Yurchenkov Svetlana A. Protsenko Alexey V. Novik Ludmila V. Vorotilina Fedor V. Moiseenko Victor L. Chang Tags: Article Source Type: research